Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Diabetes
|
October 27, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
The New England Journal of Medicine
|
September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care
|
January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
Trials
|
December 19, 2024
The IMproving treatment decisions for Patients with AortiC stenosis Through Shared Decision Making (IMPACT SDM) Study: study protocol for a cluster randomized stepped wedge trial
Karen Sepucha, Sammy Elmariah, K D Valentine, et al.
Circulation
|
September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Journal of the American College of Cardiology
|
May 27, 2026
Roadmap to Revitalizing Academic Cardiovascular Medicine: A Perspective From the Association of Professors of Cardiology (APC) Emerging Leaders Group
Sadeer Al-Kindi, Michael P Ayers, Gloria Ayuba, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
JAMA
|
March 6, 2023
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial
Neha J Pagidipati, Adam J Nelson, Lisa A Kaltenbach, et al.
The New England Journal of Medicine
|
March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
American Heart Journal
|
December 24, 2024
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics
Adam J Nelson, Lisa A Kaltenbach, Darren K McGuire, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Diabetes
|
October 27, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
The New England Journal of Medicine
|
September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care
|
January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
Trials
|
December 19, 2024
The IMproving treatment decisions for Patients with AortiC stenosis Through Shared Decision Making (IMPACT SDM) Study: study protocol for a cluster randomized stepped wedge trial
Karen Sepucha, Sammy Elmariah, K D Valentine, et al.
Circulation
|
September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Journal of the American College of Cardiology
|
May 27, 2026
Roadmap to Revitalizing Academic Cardiovascular Medicine: A Perspective From the Association of Professors of Cardiology (APC) Emerging Leaders Group
Sadeer Al-Kindi, Michael P Ayers, Gloria Ayuba, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
JAMA
|
March 6, 2023
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial
Neha J Pagidipati, Adam J Nelson, Lisa A Kaltenbach, et al.
The New England Journal of Medicine
|
March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
American Heart Journal
|
December 24, 2024
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics
Adam J Nelson, Lisa A Kaltenbach, Darren K McGuire, et al.
Page
of 9